Novel Approaches to the Treatment of Alzheimer’s Disease

  • Edwin M. Meyer
  • James W. Simpkins
  • Jyunji Yamamoto

Part of the Advances in Behavioral Biology book series (ABBI, volume 36)

Table of contents

  1. Front Matter
    Pages i-xiv
  2. Drugs That Act at Cholinergic Receptors

    1. Kenneth A. Jacobson, Barton J. Bradbury, Jesse Baumgold
      Pages 1-9
    2. Abraham Fisher, Rachel Brandeis, Ishai Karton, Zipora Pittel, Shlomit Dachir, Michal Sapir et al.
      Pages 11-16
    3. Fulton T. Crews, Norbert J. Pontzer, L. Judson Chandler
      Pages 17-24
  3. CNS-Active Neurotrophic Factors

    1. Michael B. Rosenberg, Mark H. Tuszynski, Kazunari Yoshida, Theodore Friedmann, Fred H. Gage
      Pages 95-101
    2. Lawrence R. Williams, Karen S. Jodelis, Melody R. Donald, Henry K. Yip
      Pages 103-115
    3. Eugene M. Johnson Jr., David P. Martin, Beth K. Levy, Jason Y. Chang
      Pages 127-132
    4. Dalia M. Araujo, Paul A. Lapchak, Jean-Guy Chabot, Remi Quirion
      Pages 153-163
  4. Additional Novel Treatment Strategies: Improved Brain Delivery, Hormones, and Immunology

    1. Marcus E. Brewster, Cynthia Robledo-Luiggi, Akio Miyakeb, Emil Pop, Nicholas Bodor
      Pages 173-183
    2. Kenji Matsuyama, Choichiro Miyazaki, Masataka Ichikawa
      Pages 185-196
    3. Vijendra K. Singh, Reed P. Warren
      Pages 213-220
    4. W. F. McDaniel, M. S. Schmidt, F. I. Chirino Barcelo, B. K. Davis
      Pages 221-233
  5. Models for Drug-Development: Cholinergic Hypofunction

  6. Models for Drug Development: Other Neurochemical and Behavioral Changes

    1. Kevin J. Anderson, Daniel T. Monaghan, James W. Geddes
      Pages 293-302
    2. Ralph Dawson Jr., Michael J. Meldrum, David R. Wallace
      Pages 319-328
    3. Jyunji Yamamoto
      Pages 329-345
    4. Diana S. Woodruff-Pak, Richard G. Finkbiner, Ira R. Katz
      Pages 355-371
  7. Back Matter
    Pages 383-386

About this book


Alzheimer's disease afflicts up to 1 in 5 people over the age of 65 years and causes untold suffering of the patient and their family. The cause of this disease is unknown; indeed, evidence increasingly suggests that there may be multiple Alzheimer-type syndromes with different etiologies, analogous to different types of psychosis. Currently there are no means to prevent the disease, slow its progress or reverse its neurodegenerative consequences. With few exceptions, clinical trials of a variety of compounds have resulted in patient responses that are disappointing with respect to both the proportion of responders and the magnitude of the responses. Novel approaches to the treatment of Alzheimer's disease are clearly warranted. For this reason, we organized the First Suncoast Workshop on the Neurobiology of Aging in St. Petersburg, Florida, which took place from February 26-March 1, 1989. This workshop focused on novel treatments and models for Alzheimer's disease and represented a cooperative venture among academia, government and industry, both in its participants and sponsorship. The Center for the Neurobiology of Aging at the University of Florida, the National Institute on Aging and Taiho Pharmaceutical Corporation in Japan sponsored the workshop in which scientists from the North America, Europe, Japan and other parts of Asia participated.


Alzheimer's disease Pet aging biology brain cortex growth neurobiology pharmaceutical receptor

Editors and affiliations

  • Edwin M. Meyer
    • 1
  • James W. Simpkins
    • 1
  • Jyunji Yamamoto
    • 2
  1. 1.University of FloridaGainesvilleUSA
  2. 2.Taiho Pharmaceuticals, Ltd.TokushimaJapan

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag US 1989
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4684-5729-2
  • Online ISBN 978-1-4684-5727-8
  • Series Print ISSN 0099-6246
  • Buy this book on publisher's site